ORIGINAL INVESTIGATION. Symptomatic Pulmonary Embolism and the Risk of Recurrent Venous Thromboembolism
|
|
- Caren Hunt
- 5 years ago
- Views:
Transcription
1 ORIGINAL INVESTIGATION Symptomatic Pulmonary Embolism and the Risk of Recurrent Venous Thromboembolism Sabine Eichinger, MD; Ansgar Weltermann, MD; Erich Minar, MD; Milena Stain, MD; Verena Schönauer, MD; Barbara Schneider, PhD; Paul Alexander Kyrle, MD Background: In patients with a first symptomatic pulmonary embolism (PE), the risk of recurrence is unknown. We therefore investigated the risk of recurrence among patients with spontaneous symptomatic PE and among those with deep vein thrombosis (DVT) without symptoms of PE. Methods: After discontinuation of secondary thromboprophylaxis for a first venous thromboembolism (VTE), we prospectively observed 436 patients for an average of 30 months. Patients with secondary VTE, natural inhibitor deficiencies, lupus anticoagulant, cancer, long-term antithrombotic therapy, vena cava filters, or pregnancy were excluded. The study outcome was objectively documented recurrent symptomatic VTE. Results: Recurrent VTE was seen among 28 (17.3%) of 162 patients with symptomatic PE and among 26 (9.5%) of 274 patients with DVT without symptoms of PE. Compared with patients with DVT, the relative risk of recurrent VTE among patients with symptomatic PE was 2.2 (95% confidence interval, ; P=.005). The relative risk was not affected by age, sex, presence of factor V Leiden or prothrombin G20210A, hyperhomocysteinemia, or high factor VIII levels. Compared with patients with DVT without symptoms of PE, patients with symptomatic PE had an adjusted relative risk of PE at recurrence of 4.0 (95% confidence interval, ; P=.03). Conclusion: Patients with a first symptomatic PE not only have a higher risk of recurrent VTE than those with DVT without symptoms of PE, but are also at high risk of symptomatic PE at recurrence. Arch Intern Med. 2004;164:92-96 From the Division of Hematology and Hemostasis, Department of Internal Medicine I (Drs Eichinger, Weltermann, Stain, Schönauer, and Kyrle), Division of Angiology, Department of Internal Medicine II (Dr Minar), and Institute of Medical Statistics (Dr Schneider), University of Vienna, Vienna, Austria; and Ludwig-Boltzmann Institute for Thrombosis Research, Vienna (Dr Kyrle). The authors have no relevant financial interest in this article. PULMONARY EMBOLISM (PE) IS a frequent and potentially fatal disease with an incidence of 1 in 1000 persons per year. 1-3 Approximately 10% of the patients die of heart failure and cardiac shock within hours. 4 Twentyfive percent of the patients do not survive the first year, 5,6 but many deaths during this time are related to underlying conditions, such as cancer or chronic heart disease, rather than to recurrent PE. 7,8 The prognosis of patients with PE without a predisposing illness might be more favorable, but the risk of recurrent venous thromboembolism (VTE) among these patients has never been investigated, to our knowledge. Recurrent VTE can be prevented by treatment with oral anticoagulants. 9,10 Since these drugs may cause bleeding, determining the optimal duration of anticoagulation entails balancing the risk of hemorrhage against the risk of recurrence. Pulmonary embolism is regarded as the consequence of deep vein thrombosis (DVT) rather than a separate clinical entity. Most trials on the risk of recurrent VTE therefore did not distinguish between patients with DVT and those with PE. 9,10,14,15 Since the risk of recurrence is thus unknown in patients with PE, the decision as to how long these patients should receive anticoagulation is subject to individual preference rather than objective guidelines. We observed 436 patients with a first spontaneous VTE and compared the risk of recurrence between patients with symptomatic PE and those with DVT without symptoms of PE. METHODS PATIENT POPULATION Between July 1, 1992, and June 30, 2002, 1056 consecutive patients (older than 18 years) with DVT of the leg and/or PE, who had been treated with oral anticoagulants for at least 3 months, were eligible. A total of 592 patients were excluded because of surgery, trauma, or preg- 92
2 nancy within the previous 3 months; previously recurrent VTE; deficiency of antithrombin, protein C, or protein S; presence of the lupus anticoagulant; cancer; requirement for long-term antithrombotic treatment; or a vena cava filter. All patients had been treated with unfractionated or low-molecular-weight heparin in therapeutic dosages. Twenty-one patients with PE had received thrombolytic therapy. Patients entered the study at the time of discontinuation of oral anticoagulants and were then seen at 3-month intervals during the first year and every 6 months thereafter. They received written information on the symptoms of VTE and were instructed to report if such symptoms occurred. The study was approved by the ethics committee of the Vienna University Hospital, Vienna, Austria, and all patients provided written informed consent before inclusion. DIAGNOSIS OF VTE The diagnosis of DVT was established by a positive finding on venography or color duplex sonography (in case of proximal DVT). To be considered positive, the venograms had to meet at least 1 of the following direct or indirect criteria: a constant filling defect seen on 2 views; an abrupt discontinuation of the contrast-filled vessel at a constant level of the vein; and the absence of filling in the entire deep vein system (without compression), with or without venous flow through collateral veins. With color duplex ultrasonography, at least 1 of the 2 following criteria for DVT had to be met: visualization of an intraluminal thrombus in a deep vein and incomplete compressibility or absence of compressibility. A diagnosis of PE was considered if the patient had typical symptoms (chest pain, dyspnea, cough, hemoptysis, and/or syncope). The diagnosis of PE was then confirmed either by a positive finding on ventilation-perfusion scanning according to the criteria of the Prospective Investigation of Pulmonary Embolism Diagnosis 16 or by spiral computed tomography demonstrating 1 or several low-attenuation areas that partly or completely filled the lumen of an opacified vessel. STUDY END POINTS The end point of the study was recurrent symptomatic DVT confirmed by venography or color duplex sonography (in case of proximal DVT of the contralateral leg) or recurrent symptomatic PE confirmed by ventilation-perfusion scanning and/or spiral computed tomography according to the aforementioned criteria. The DVT was considered to have recurred if the patient had a thrombus in the leg opposite from that affected by the previous thromboembolic event; a thrombus in another deep vein in the same leg as the previous event; or a thrombus in the same venous system as the previous event, with proximal extension of the thrombus (if the upper limit of the original thrombus had been visible) or with a constant filling defect surrounded by contrast medium (if the original thrombus had not been visible). The diagnosis was established by an adjudication committee consisting of independent clinicians and radiologists. LABORATORY ANALYSIS Blood was collected, after fasting, into 1:10 volume of 0.11mM trisodium citrate and immediately centrifuged for 20 minutes at 2000g. The plasma was stored at 80 C. Genomic DNA was isolated from leukocytes by standard methods. Screening for factor V Leiden and for prothrombin G20210A was carried out as described. 17,18 Determination of antithrombin, protein C, protein S, total homocysteine, and factor VIII was performed as previously reported. 19 The diagnosis of a lupus anticoagulant was based on the criteria of the International Society of Thrombosis and Haemostasis. 20 The technicians were unaware of the patient characteristics at all times. STATISTICAL ANALYSIS Times to recurrence (uncensored observations) or follow-up times in patients without recurrence (censored observations) were analyzed by survival time methods. 21 The probability of recurrence was estimated according to Kaplan-Meier. 22 To test for homogeneity between strata, we applied the log-rank and the generalized Wilcoxon test. The data were adjusted for age, sex, factor V Leiden, prothrombin G20210A, hyperhomocysteinemia (dichotomized at the 95th percentile of the reference range), and high factor VIII level (dichotomized at a plasma level of 234%). Categorical data were checked for homogeneity by means of contingency table analyses ( 2 test). Simple descriptive statistics were computed to provide a clear presentation of the data. For numerical operations, an SAS software package (SAS Institute Inc, Cary, NC) was used. Values are given as mean±sd. RESULTS Of 464 patients, 162 patients had PE and 302 patients had DVT. Symptoms of PE were chest pain in 104 patients (64%), dyspnea in 116 patients (72%), cough or hemoptysis in 37 patients (23%), and syncope in 27 patients (17%). Twenty-eight patients with DVT were excluded because they had symptoms of PE but objective testing was not performed. The characteristics of the remaining 436 study patients (274 with DVT without symptoms of PE and 162 with symptomatic PE) are shown in Table 1. There was no significant difference between patients with symptomatic PE and patients with DVT without symptoms of PE with regard to age, sex distribution, the presence of factor V Leiden or prothrombin G20210A, hyperhomocysteinemia, or high factor VIII level. Patients with symptomatic PE had a shorter observation time and received anticoagulants significantly longer than patients with DVT. One hundred twenty-three patients left the study. Seven did so because they were given a diagnosis of cancer and 82 because they required antithrombotic therapy for reasons other than VTE. Twenty-eight patients (6%) were lost to follow-up. Six patients died, but recurrent VTE was the cause of death in none of them. The patients data were censored at the time of exclusion or death. Recurrent VTE (39 DVT without symptoms of PE, 15 symptomatic PE) occurred in 54 patients (12.4%). Thirty-nine patients with recurrence were male and 15 patients were female. The proportion of patients with high factor VIII levels was higher among patients with recurrence than among patients without recurrence (11 patients [20%] and 37 patients [9%], respectively; P=.01). There was no significant difference between patients with and without recurrence with regard to age (50±16 years and 47±18 years, respectively), the presence of factor V Leiden (16 patients [30%] and 135 patients [33%], respectively) or prothrombin G20210A (9 patients [17%] and 37 patients [9%], respectively), or the proportion of patients with hyperhomocysteinemia (16 patients [30%] 93
3 Table 1. Baseline Characteristics of the 436 Patients Characteristic DVT Without Symptoms of PE (n = 274) (n = 162) P Value Age at venous thromboembolism, mean ± SD, y 48 ± ± Sex, No. (%) female 158 (58) 91 (56).80 Duration of oral anticoagulant therapy, mean ± SD, mo 8 ± ± Factor V Leiden, No. (%) 95 (36) 42 (27).06 Prothrombin G20210A, No. (%) 25 (9) 16 (10).80 Hyperhomocysteinemia, No. (%) 61 (24) 47 (31).10 High factor VIII ( 234%), No. (%) 30 (11) 15 (10).60 Observation time, mean ± SD, mo 32 ± ± Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism. Cumulative Probability of Recurrence, % No. of Patients at Risk DVT Without Symptoms of PE DVT Without Symptoms of PE Months After Oral Anticoagulants P = Kaplan-Meier estimates of the risk of recurrent venous thromboembolism in patients with symptomatic pulmonary embolism (PE) or deep vein thrombosis (DVT) without symptoms of PE. and 107 patients [26%], respectively). In none of the patients was the episode of recurrent VTE fatal. Recurrent VTE occurred in 28 (17.3%) of the 162 patients with symptomatic PE and in 26 (9.5%) of the 274 patients with DVT without symptoms of PE. A Kaplan-Meier analysis showed a significant divergence between the rate of recurrence among patients with symptomatic PE and among patients with DVT without symptoms of PE (Figure). At 24 months, the likelihood of recurrence was 19% (95% confidence interval, 12%-26%) among patients with symptomatic PE compared with 7% (95% confidence interval, 3%-11%) among patients with DVT (P=.004). A first symptomatic PE conferred a relative risk of recurrence of 2.2 (95% confidence interval, ; P=.005) (Table 2) and remained an independent risk factor for recurrence after adjustment for age, sex, the presence of factor V Leiden or prothrombin G20210A, hyperhomocysteinemia, or high factor VIII level (relative risk, 2.2; 95% confidence interval, ; P=.005). Patients with symptomatic PE had a high risk of a subsequent symptomatic PE. Compared with patients with DVT without symptoms of PE, the relative risk of PE at recurrence among patients with a first symptomatic PE was 4.0 (95% confidence interval, ; P=.03) after adjustment for other potentially confounding thrombotic risk factors COMMENT Our prospective study demonstrates that the risk of recurrent VTE is significantly higher among patients with symptomatic PE than among patients with DVT without symptoms of PE. In a prospective study of 436 patients, the risk of recurrence was more than twice as great among patients with a first spontaneous symptomatic PE as among those with DVT without symptoms of PE. Most important, patients with symptomatic PE had a 4-fold higher risk of symptomatic PE at recurrence than patients with DVT. Our findings are in agreement with those of the Columbus Investigators, who compared the efficacy of lowmolecular-weight and unfractionated heparin in patients with VTE. 23 At 3 months, the rate of recurrence was higher among patients with PE (5.9%) than among patients with DVT (4.8%). That study, however, was neither intended nor powered to compare the rate of recurrence between patients with PE and DVT. The observation of a high risk of PE at recurrence among patients with an incident symptomatic PE corroborates findings of 2 recent studies. In a metaanalysis, Douketis and coworkers 24 found a higher rate of fatal recurrent PE in patients with PE (1.4%) than the rate of a fatal first PE after treatment for DVT (0.3%). In a retrospective cohort study, the initial clinical manifestation of VTE strongly predicted the same clinical presentation among patients rehospitalized for recurrent thromboembolism. 25 Among patients with PE who developed recurrence, 70% were diagnosed as having PE and 30% were diagnosed as having venous thrombosis alone, whereas among patients with venous thrombosis and recurrence, only 15% were diagnosed as having PE and 85% had venous thrombosis. The different rates of recurrence among patients with symptomatic PE and those with DVT without symptoms of PE do not result from an incidentally unbalanced distribution of thrombotic risk factors among the 2 groups. We have excluded patients with potent risk factors for recurrence, such as previous thrombosis, cancer, or the lupus anticoagulant, as well as low-risk patients with thrombosis related to surgery, trauma, or pregnancy. We excluded neither patients with high factor VIII level, who have a high risk of recurrence, 19 nor carriers of factor V Leiden or prothrombin G20210A, in whom we reported a risk of recurrence similar to that in 94
4 Table 2. Relative Risk of Recurrent Venous Thromboembolism VTE at Recurrence PE at Recurrence Relative Risk (95% CI) Relative Risk (95% CI) Recurrence, No. Univariate Multivariate* Recurrence, No. Univariate Multivariate* DVT without symptoms of PE (n = 274) (n = 162) ( ) 2.2 ( ) ( ) 4.0 ( ) Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism. *Adjusted for age, sex, factor V Leiden, prothrombin G20210A, hyperhomocysteinemia, high factor VIII, and duration of anticoagulation. Reference group. noncarriers of these mutations. 26,27 However, the proportion of patients with either of these risk factors was not significantly different between patients with symptomatic PE and patients with DVT without symptoms of PE. Also, symptomatic PE remained an independent risk factor for recurrent VTE after adjustment for these risk factors in the multivariate analysis. The duration of secondary thromboprophylaxis in patients with symptomatic PE was significantly longer than that in patients with DVT without symptoms of PE (11 vs 8 months on average, respectively). This difference can be explained by individual treatment preferences of the supervising physician. Since a longer duration of oral anticoagulation is associated with a lower rate of recurrence, the difference between the 2 groups with respect to the risk of recurrence might have been even greater in the case of a shorter duration of anticoagulation in the patients with PE. In approximately 40% of the patients with proximal DVT, perfusion scan findings consistent with PE can be found in the absence of clinical symptoms. 28 In our study, visualization techniques were not performed on a routine basis, but only in patients who presented with symptoms suggestive for PE. Therefore, some of our patients categorized as having DVT also had asymptomatic PE. Our patient classification would have affected our results only if asymptomatic PE would confer a lower risk of recurrence, which is very unlikely. Assuming that patients with asymptomatic PE have a higher risk of recurrence than patients with DVT without PE, the difference in the rate of recurrence between patients with PE (regardless of the presence or absence of symptoms) and patients with DVT without symptoms of PE would have been even greater. Nevertheless, the risk of recurrence among patients with asymptomatic PE ought to be investigated. Our findings have 2 major clinical implications. To identify patients at high risk of recurrent VTE, a careful clinical examination of patients with DVT with regard to the presence of symptoms suggestive of PE is of utmost importance. Recurrent VTE is associated with serious clinical consequences: it is fatal in approximately 5% of the patients, 24,29 and it is associated with the postthrombotic syndrome in one third of patients. 30 Since the risk of recurrence and, thus, its complications can be reduced by treatment with anticoagulants, the results of our study indicate that prospective trials are warranted to investigate the optimal duration of secondary thromboprophylaxis in patients with PE. Accepted for publication February 21, This study was supported by grant 1980 from the Medizinisch-Wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien, Vienna, Austria. Corresponding author and reprints: Sabine Eichinger, MD, Division of Hematology and Hemostasis, Department of Internal Medicine I, Waehringer Guertel 18-20, A-1090 Vienna, Austria ( sabine.eichinger@akh-wien.ac.at). REFERENCES 1. Andersen FA Jr, Wheeler HB, Goldbery RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991;151: Kniffin WD, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep vein thrombosis in the elderly. Arch Intern Med. 1994;154: Silverstein MD, Heit JA, Mohr DN, Petterson TM, O Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158: Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975;17: Goldhaber SZ, Visani L, De Rosa M, for the International Cooperative Pulmonary Embolism Registry (ICOPR). Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry. Lancet. 1999;353: Goldhaber SZ. Pulmonary embolism. N Engl J Med. 1998;339: Carson JL, Kelly MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326: Van Beek EJR, Kuijer PMM, Büller HR, Brandjes DP, Bossuyt PM, ten Cate JW. The clinical course of patients with suspected pulmonary embolism. Arch Intern Med. 1997;157: Schulman S, Rhedin AS, Lindmarker P, et al, Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995; 332: Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340: Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT): Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348: van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost. 1996;76: Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 2001;119(1, suppl):108s-113s. 95
5 14. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103: Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med. 2001;345: PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA. 1990;263: Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369: Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3 -untranslated region of the prothrombin gene. Blood. 1996;88: Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343: Brandt JT, Triplett DA, Alving B, Scharrer I, for the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74: Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337: Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279: Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep vein thrombosis or pulmonary embolism. Thromb Haemost. 2002;88: Eichinger S, Pabinger I, Stümpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997; 77: Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81: Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep vein thrombosis. JAMA. 1994;271: Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125: Prandoni P, Lensing AW, Prins MR. Long-term outcomes after deep venous thrombosis of the lower extremities. Vasc Med. 1998;3: Correction Error in Text. In the Original Investigation by Civitelli et al titled Alveolar and Postcranial Bone Density in Postmenopausal Women Receiving Hormone/ Estrogen Replacement Therapy: A Randomized, Double-blind, Placebo- Controlled Trial, published in the June 24, 2002, issue of the ARCHIVES (2002; 162: ), the dosage of cholecalciferol was incorrectly given as 800 IU/ d, instead of the correct dosage 400 IU/d. 96
The Risk of Recurrent Venous Thromboembolism in Men and Women
The new england journal of medicine original article The Risk of Recurrent Venous Thromboembolism in Men and Women Paul A. Kyrle, M.D., Erich Minar, M.D., Christine Bialonczyk, M.D., Mirko Hirschl, M.D.,
More informationHIGH PLASMA LEVELS OF FACTOR VIII AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM
HIGH PLASMA LEVELS OF FACTOR VIII AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM HIGH PLASMA LEVELS OF FACTOR VIII AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM PAUL A. KYRLE, M.D., ERICH MINAR, M.D.,
More informationChapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families
Chapter A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families Willem M. Lijfering Nic J.G.M. Veeger Saskia Middeldorp Karly Hamulyák Martin
More informationThe risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study
Journal of Thrombosis and Haemostasis, 12: 635 640 DOI: 10.1111/jth.12528 ORIGINAL ARTICLE The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study
More informationDEEP VENOUS THROMBOSIS AMONG CARRIERS OF FACTOR V LEIDEN AND THE G20210A PROTHROMBIN MUTATION
DEEP VENOUS THROMBOSIS AMONG CARRIERS OF FACTOR V LEIDEN AND THE G20210A PROTHROMBIN MUTATION THE RISK OF RECURRENT DEEP VENOUS THROMBOSIS AMONG HETEROZYGOUS CARRIERS OF BOTH FACTOR V LEIDEN AND THE G20210A
More informationAfter a first episode of acute venous thromboembolism
Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia Gualtiero
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationHematocrit and the Risk of Recurrent Venous Thrombosis: A Prospective Cohort Study
Hematocrit and the Risk of Recurrent Venous Thrombosis: A Prospective Cohort Study Lisbeth Eischer 1, Verena Tscholl 1, Georg Heinze 2, Ludwig Traby 1, Paul A. Kyrle 1, Sabine Eichinger 1 * 1 Department
More informationRecurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism
ARTICLES Coagulation & its Disorders Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism Tom van der Hulle, Melanie Tan, Paul L. den Exter, Mark J.G.
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21764 holds various files of this Leiden University dissertation. Author: Mos, Inge Christina Maria Title: A more granular view on pulmonary embolism Issue
More informationPatients with venous thromboembolism (VTE) that occurs
D-Dimer Levels Over Time and the Risk of Recurrent Venous Thromboembolism: An Update of the Vienna Prediction Model Sabine Eichinger, MD; Georg Heinze, PhD; Paul A. Kyrle, MD Background- Patients with
More informationACR Appropriateness Criteria Suspected Lower Extremity Deep Vein Thrombosis EVIDENCE TABLE
. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg 003; 5():-5.. Hamper UM, DeJong MR, Scoutt LM. Ultrasound
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationVascular Medicine. Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism The Vienna Prediction Model
Vascular Medicine Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism The Vienna Prediction Model Sabine Eichinger, MD*; Georg Heinze, PhD*; Lisanne M.
More informationPatients with venous thromboembolism (VTE) that occurs
D-Dimer Levels Over Time and the Risk of Recurrent Venous Thromboembolism: An Update of the Vienna Prediction Model Sabine Eichinger, MD; Georg Heinze, PhD; Paul A. Kyrle, MD Background- Patients with
More informationRECURRENT VENOUS THROMBOEMBOLISM AND MUTATION IN THE GENE FOR FACTOR V
THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH AN Arg 506 Gln MUTATION IN THE GENE FOR FACTOR V (FACTOR V LEIDEN) PAOLO SIMIONI, M.D., PAOLO PRANDONI, M.D., PH.D., ANTHONIE W.A. LENSING,
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationCausative factors of deep vein thrombosis of lower limb in Indian population
International Surgery Jthisnal Khadilkar R et al. Int Surg J. 18 Jan;(1):3-3 http://www.ijsurgery.com pissn 39-33 eissn 39-9 Original Research Article DOI: http://dx.doi.org/1.183/39-9.isj17919 Causative
More informationVenous thromboembolism (VTE) is a common disease. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women
Menopause: The Journal of The North American Menopause Society Vol. 18, No. 5, pp. 488/493 DOI: 10.1097/gme.0b013e3181f9f7c3 * 2011 by The North American Menopause Society Hormone therapy and recurrence
More informationDuration of Therapy for Venous Thromboembolism
Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee
More informationORIGINAL INVESTIGATION. Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism
Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism A Population-Based Cohort Study ORIGINAL INVESTIGATION John A. Heit, MD; David N. Mohr, MD; Marc D. Silverstein, MD; Tanya M.
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationVenous thromboembolism (VTe) affects approximately
The Journal of The american osteopathic association Duration of Anticoagulation Treatment in Patients With Venous Thromboembolism Scott Kaatz, DO, MSc; Waqas Qureshi, MD; Christopher Fain, DO; and David
More informationThe shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism
Eur Respir J 211; 37: 762 766 DOI: 1.1183/931936.711 CopyrightßERS 211 The shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism A. Sam*, D. Sánchez*,
More informationTHE INCIDENCE RATE OF A FIRST
ORIGINAL CONTRIBUTION Thrombophilia, Clinical Factors, and Recurrent Venous Thrombotic Events Sverre C. Christiansen, MD Suzanne C. Cannegieter, MD, PhD Ted Koster, MD, PhD Jan P. Vandenbroucke, MD, PhD
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism
More informationDeep vein thrombosis (DVT) is a pervasive LOW-MOLECULAR-WEIGHT HEPARIN IN THE TREATMENT OF ACUTE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM *
LOW-MOLECULAR-WEIGHT HEPARIN IN THE TREATMENT OF ACUTE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM * Geno J. Merli, MD ABSTRACT There are more than 170 000 hospital admissions each year for deep vein thrombosis
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/188/20915 holds various files of this Leiden University dissertation. Author: Flinterman, Linda Elisabeth Title: Risk factors for a first and recurrent venous
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationThe Epidemiology of Venous Thromboembolism
The Epidemiology of Venous Thromboembolism Richard H. White, MD Abstract Venous thromboembolism (VTE) occurs for the first time in 100 persons per 100,000 each year in the United States, and rises exponentially
More informationClinically Suspected Acute Recurrent Pulmonary Embolism: A Diagnostic Challenge
7 Clinically Suspected Acute Recurrent Pulmonary Embolism: A Diagnostic Challenge M. Nijkeuter, H. Kwakkel- van Erp, M. Sohne, L.W. Tick, M.J.H.A. Kruip, E.F. Ullmann, M.H.H Kramer, H.R. Büller, M.H. Prins,
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationChapter 1. Introduction
Chapter 1 Introduction Introduction 9 Even though the first reports on venous thromboembolism date back to the 13 th century and the mechanism of acute pulmonary embolism (PE) was unraveled almost 150
More informationSession Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD
Thrombosis II Session Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD Inherited Risk Factors for Venous Thrombosis Mary Cushman Venous
More informationUpper-extremity deep vein thrombosis (DVT) is a rare
Vascular Medicine Risk Factors and Recurrence Rate of Primary Deep Vein Thrombosis of the Upper Extremities Ida Martinelli, MD, PhD; Tullia Battaglioli, MD; Paolo Bucciarelli, MD; Serena Maria Passamonti,
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationIncidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
The new england journal of medicine original article Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism Vittorio Pengo, M.D., Anthonie W.A. Lensing, M.D., Martin H. Prins,
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 16 December 1999 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL
More informationORIGINAL INVESTIGATION
Use of a Clinical Decision Rule in Combination With D-Dimer Concentration in Diagnostic Workup of Patients With Suspected Pulmonary Embolism A Prospective Management Study ORIGINAL INVESTIGATION Marieke
More informationThe etiology, diagnosis and treatment of venous thromboembolism Kraaijenhagen, R.A.
UvA-DARE (Digital Academic Repository) The etiology, diagnosis and treatment of venous thromboembolism Kraaijenhagen, R.A. Link to publication Citation for published version (APA): Kraaijenhagen, R. A.
More informationElevated Plasma Factor VIII and d-dimer Levels as Predictors of Poor Outcomes of Thrombosis in Children
The new england journal of medicine original article Elevated Plasma Factor VIII and d-dimer Levels as Predictors of Poor Outcomes of Thrombosis in Children Neil A. Goldenberg, M.D., R. Knapp-Clevenger,
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationShould Patients with Venous Thromboembolism Be Screened for Thrombophilia?
REVIEW Should Patients with Venous Thromboembolism Be Screened for Thrombophilia? James E. Dalen, MD, MPH University of Arizona, Tucson. ABSTRACT In the mid-19th century, Virchow identified hypercoagulability
More informationIncidence of Diagnosed Deep Vein Thrombosis in the General Population: Systematic Review
Eur J Vasc Endovasc Surg 25, 1±5 (2003) doi:10.1053/ejvs.2002.1778, available online at http://www.sciencedirect.com on REVIEW Incidence of Diagnosed Deep Vein Thrombosis in the General Population: Systematic
More informationPulmonary Thromboembolism
Pulmonary Thromboembolism James Allen, MD Epidemiology of Pulmonary Embolism 1,500,000 new cases per year in the United States Often asymptomatic 300,000 deaths per year DVT or PE present in 10% of ICU
More informationDeep Vein Thrombosis: Can a Second Sonographic Examination Be Avoided?
Alfonsa Friera 1 Nuria R. Giménez 2 Paloma Caballero 1 Pilar S. Moliní 2 Carmen Suárez 2 Received August 15, 2001; accepted after revision October 16, 2001. 1 Radiology Department, Hospital de la Princesa,
More informationEpidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer
Blood Coagulation, Fibrinolysis and Cellular Haemostasis 255 Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer Carlos Martinez
More informationA Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism
Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew
More informationNatural History of Venous Thromboembolism Clive Kearon DOI: /01.CIR
Natural History of Venous Thromboembolism Clive Kearon Circulation 2003;107;I-22-I-30 DOI: 10.1161/01.CIR.0000078464.82671.78 Circulation is published by the American Heart Association. 7272 Greenville
More informationDifferences in clinical presentation of pulmonary embolism in women and men
Journal of Thrombosis and Haemostasis, 8: 693 698 DOI: 10.1111/j.1538-7836.2010.03774.x ORIGINAL ARTICLE Differences in clinical presentation of pulmonary embolism in women and men H. ROBERT-EBADI,* G.
More informationTreatment of Deep-Vein Thrombosis
The new england journal of medicine clinical practice Treatment of Deep-Vein Thrombosis Shannon M. Bates, M.D.C.M., and Jeffrey S. Ginsberg, M.D. This Journal feature begins with a case vignette highlighting
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More informationDuration of Anticoagulation: Applying the Guidelines and Beyond
ISSUES IN THROMBOSIS MANAGEMENT AND ANTICOAGULATION Duration of Anticoagulation: Applying the Guidelines and Beyond Kenneth A. Bauer 1,2 1 Hematology Section, VA Boston Healthcare System and Beth Israel
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1999, by the Massachusetts Medical Society VOLUME 340 M ARCH 25, 1999 NUMBER 12 A COMPARISON OF THREE MONTHS OF ANTICOAGULATION WITH EXTENDED ANTICOAGULATION
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationVenous thromboembolism is a common, potentially
CMAJ Research Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy Marc A. Rodger MD MSc, Susan R. Kahn MD MSc, Philip S. Wells MD MSc, David
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationThis chapter will describe the effectiveness of antithrombotic
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS,
More informationGenetics. Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A
Genetics Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A Willem M. Lijfering, MD, PhD; Saskia Middeldorp, MD, PhD;
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationThrombophilia testing: who is it good for? F.R. Rosendaal, Leiden
Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden Inaugural meeting of Iranian Society on Thrombosis and Haemostasis Mofid Children Hospital Tehran, 24 December 2015 Chest. 2012;141(2_suppl):e48S-e801S
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationDeep venous thrombosis (DVT) is a common problem among
Update When Can the Patient With Deep Venous Thrombosis Begin to Ambulate? Deep venous thrombosis (DVT) is a common problem among hospitalized patients, 1 even those who receive prophylaxis. 2 Patients
More informationPredicting the risk of recurrent venous thromboembolism (VTE)
J Thromb Thrombolysis (2015) 39:353 366 DOI 10.1007/s19-015-1188-4 Predicting the risk of recurrent venous thromboembolism (VTE) Michael B. Streiff Published online: 27 February 2015 Ó Springer Science+Business
More informationDeep Venous Thrombosis : Five Years Analysis at Prapokklao Hospital
184 Ÿπ å» æ» µ å π ßæ æ ª â ªï Ë 21 Ë 4 µ.. -.. 2547 π æπ åµâπ Deep Venous Thrombosis : Five Years Analysis at Prapokklao Hospital Piyapong Permlarp M.D.* Abstract Objective : To determine the age, sex,
More informationOne of every 3 to 4 patients with symptomatic proximal
Annals of Internal Medicine Article Below-Knee Elastic Compression Stockings To Prevent the Post-Thrombotic Syndrome A Randomized, Controlled Trial Paolo Prandoni, MD, PhD; Anthonie W.A. Lensing, MD, PhD;
More informationProper Diagnosis of Venous Thromboembolism (VTE)
Proper Diagnosis of Venous Thromboembolism (VTE) Whal Lee, M.D. Seoul National University Hospital Department of Radiology 2 nd EFORT Asia Symposium, 3 rd November 2010, Taipei DVT - Risk Factors Previous
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationBACKGROUND METHODS RESULTS CONCLUSIONS
CHAPTER 5 The combination of a normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to exclude deep venous thrombosis R.E.G. Schutgens 1, P. Ackermark 2, F.J.L.M.
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationPROGNOSIS AND SURVIVAL
CANCER ASSOCIATED THROMBOSIS PROGNOSIS AND SURVIVAL Since French internist Armand Trousseau reported the occurrence of mysterious thrombotic disorders in cancer patients in the mid-19th century, the link
More informationDoes the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis
Journal of Thrombosis and Haemostasis, 8: 2436 2442 DOI: 10.1111/j.1538-7836.2010.04022.x ORIGINAL ARTICLE Does the clinical presentation and extent of venous thrombosis predict likelihood and type of
More informationORIGINAL INVESTIGATION. predictive value for compression ultrasonography. for Deep Vein Thrombosis in Symptomatic Outpatients
ORIGINAL INVESTIGATION Predictive Value of Compression Ultrasonography for Deep Vein Thrombosis in Symptomatic Outpatients Clinical Implications of the Site of Vein Noncompressibility Brian G. Birdwell,
More informationComparison between Critical Pathway Guidelines and Management of Deep-Vein Thrombosis: Retrospective Cohort Study
41(2):163-167,2000 CLINICAL SCIENCES Comparison between Critical Pathway Guidelines and Management of Deep-Vein Thrombosis: Retrospective Cohort Study Nikša Vuèiæ, Nada Lang, Stjepan Baliæ, Vladimir Pilaš,
More informationIn which direction, and how aggressively,
Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Evaluating idiopathic venous thromboembolism: What is necessary, what is not Charles F. S. Locke, MD Johns Hopkins Community
More informationPRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES
PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES Mario Mandalà, MD Unit of Clinical Research Department of Oncology and Haematology Papa Giovanni XXIII Hospital Cancer Center
More informationHISTORICALLY, INSERTION
ORIGINAL INVESTIGATION A Population-Based Study of Inferior Vena Cava Filters in Patients With Acute Venous Thromboembolism Frederick A. Spencer, MD; Shannon M. Bates, MD; Robert J. Goldberg, PhD; Darleen
More informationRisk of recurrent venous thrombosis in children with combined prothrombotic risk factors
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors Ulrike Nowak-Göttl, Ralf Junker, Wolfhart Kreuz, Arnold
More informationDOPPLER ULTRASOUND OF DEEP VENOUS THROMBOSIS
TOKUDA HOSPITAL SOFIA DOPPLER ULTRASOUND OF DEEP VENOUS THROMBOSIS MILENA STANEVA, MD, PhD Department of vascular surgery and angiology Venous thromboembolic disease continues to cause significant morbidity
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationIs thromboprophylaxis effective in reducing the pulmonary thromboembolism?
Is thromboprophylaxis effective in reducing the pulmonary thromboembolism? Fereshteh Rajabi (1), Masoumeh Sadeghi (2), Fereshteh Karbasian (3), Ali Torkan (4) Abstract BACKGROUND: Deep vein thrombosis
More informationFrom the Departments of Medicine, University of Ottawa, Ottawa, Canada, McMaster University, Hamilton, Canada, Dalhousie University, Halifax, Canada
2000 Schattauer Verlag, Stuttgart Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer Philip S. Wells,
More informationOptimizing diagnostic testing for venous thromboembolism
REVIEW CME CREDIT LEARNING OBJECTIVE: Readers will take a thoughtful approach to diagnosing venous thromboembolism and screening for thrombophilic disorders PATRICK RENDON, MD Assistant Professor, Department
More informationDave Duddleston, MD VP and Medical Director Southern Farm Bureau Life
Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Sources of Risk for Venous Diseases Pulmonary embolism (thrombus) Bleeding from anticoagulation Mortality from underlying disease Chronic
More informationGenetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수
Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationSimplified approach to investigation of suspected VTE
Simplified approach to investigation of suspected VTE Diagnosis of DVT and PE THSNA 2016, Chicago 15 April 2016 Clive Kearon, McMaster University, Canada Relevant Disclosures Research Support/P.I. Employee
More informationAdjustments in the diagnostic work-up, treatment and prognosis of pulmonary embolism van Es, Josien
UvA-DARE (Digital Academic Repository) Adjustments in the diagnostic work-up, treatment and prognosis of pulmonary embolism van Es, Josien Link to publication Citation for published version (APA): van
More informationInherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD
Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis
More informationSpontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren
Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker
More informationHow we diagnose and treat deep vein thrombosis
How I treat How we diagnose and treat deep vein thrombosis Jack Hirsh and Agnes Y. Y. Lee Making a diagnosis of deep vein thrombosis (DVT) requires both clinical assessment and objective testing because
More informationTHROMBOPHILIA SCREENING
THROMBOPHILIA SCREENING Introduction The regulation of haemostasis Normally, when a clot occurs, it exactly occurs where it has to be and does not grow more than necessary due to the action of the haemostasis
More informationDiagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism
More informationA study of clinical profile of 50 patients deep venous thrombosis at general hospital
Research Article A study of clinical profile of 50 patients with deep venous thrombosis at general hospital Kasabe P S 1, Jaykar R D 2, Lakhpatre S B 3* 1 Assistant professor, 2 Associate professor, 3
More informationCerebral sinus-venous thrombosis (CSVT) is a rare disease
Vascular Medicine Long-Term Evaluation of the Risk of Recurrence After Cerebral Sinus-Venous Thrombosis Ida Martinelli, MD, PhD; Paolo Bucciarelli, MD; Serena M. Passamonti, MD; Tullia Battaglioli, MD;
More information